Nanoco’s H1 results reflect the slow commercialisation cycle in display although H2 should improve significantly as the first payments from the company’s large, US-listed corporate partner boost revenues and cash flows. While visibility is still limited, the scale of investment and additional capacity being added indicate that the potential from this partnership is significant. Progress in lighting and medical imaging also remind us of the potential of Nanoco’s IP and expertise across a range of applications.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.